- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Muscle invasive bladder cancer (MIBC)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.7MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 1.0MB)
Durvalumab – November 2025
Durvalumab: Solution concentrate for I.V infusion, 120 mg in 2.4 mL Solution concentrate for I.V. infusion, 500 mg in 10 mL; Imfinzi® - November 2025
Last updated
5 November 2025